ABSTRACT Background: The Global Registry on Long-Term Oral Antithrombotic Treatment
in Patients with Atrial Fibrillation (GLORIA-AF) is a multinational, prospective, 3-phase study …

Background: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke
prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of …

Background: In the RELY trial, the novel oral anticoagulant (NOAC) dabigatran has been
found to be at least as effective and safe as warfarin for stroke prevention in atrial fibrillation …

Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …

Objective new oral anticoagulants (apixaban, dabigatran and rivaroxaban) are the newest
advance for stroke's risk reduction in atrial fibrillation. These are as effective as warfarin in …

Patients with atrial fibrillation at moderate to high risk of stroke are not always anticoagulated
despite a lack of contraindications to vitamin K antagonists (VKAs) like warfarin. These …

Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary
and secondary stroke prevention and prevention of systemic embolism in patients with atrial …

Because atrial fibrillation is associated with advanced age and obesity, its prevalence is
increasing worldwide. 1 New treatments such as ablation and left atrial occlusion may …

Background and purpose GLORIA-AF is a large, global, prospective registry program of
newly diagnosed atrial fibrillation (AF) patients with≥ 1 stroke risk factors. We describe the …

OBJECTIVE: Dabigatran is a nov-el target specific oral anticoagulant for stroke prevention in
non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety …